Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Harvard Business School
Farmers Insurance
Express Scripts
Accenture
Cantor Fitzgerald
US Department of Justice
UBS
Johnson and Johnson
Novartis

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 4,587,258

« Back to Dashboard

Summary for Patent: 4,587,258
Title: Angiotensin-converting enzyme inhibitors
Abstract:Novel compounds with angiotensin-converting enzyme inhibitory activity are disclosed. Such compounds are useful in the treatment of cardiovascular disorders, especially hypertension and congestive heart failure, and are useful in the treatment of glaucoma.
Inventor(s): Gold; Elijah H. (West Orange, NJ), Neustadt; Bernard R. (West Orange, NJ), Smith; Elizabeth M. (Verona, NJ)
Assignee: Schering Corporation (Kenilworth, NJ)
Application Number:06/635,390
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 4,587,258

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 4,587,258

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
81108348.4Oct 15, 1981

International Patents Family Members for US Patent 4,587,258

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 20469 ➤ Subscribe
Australia 4671885 ➤ Subscribe
Australia 554362 ➤ Subscribe
Australia 581919 ➤ Subscribe
Australia 7661481 ➤ Subscribe
Canada 1244041 ➤ Subscribe
Canada 1341206 ➤ Subscribe
Cyprus 1469 ➤ Subscribe
Czech Republic 9104138 ➤ Subscribe
Germany 19575012 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
US Army
Farmers Insurance
Mallinckrodt
Harvard Business School
Baxter
McKesson
Teva
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot